GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Catalyst Pharmaceuticals
Catalyst Pharmaceuticals specializes in treating rare neuromuscular diseases. Its stock price is largely dependent on sales of its only commercial drug, Firdapse, and its ability to protect it from competition.
Share prices of companies in the market segment - Neuro
Catalyst Pharmaceuticals is a biopharmaceutical company focused on treating rare neurological diseases. Its business consists of a single segment, driven by its lead drug, Firdapse. We classify it as part of the Neuro sector, and the chart below reflects the dynamics of the entire biotech industry working in this complex field.
Broad Market Index - GURU.Markets
Catalyst Pharmaceuticals is a biopharmaceutical company specializing in developing drugs for rare neurological diseases. Its focus on this niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Catalyst compares to it.
Change in the price of a company, segment, and market as a whole per day
CPRX - Daily change in the company's share price Catalyst Pharmaceuticals
The daily fluctuations of Catalyst Pharmaceuticals, which specializes in rare neuromuscular diseases, reflect the risks of the pharmaceutical sector. Change_co measures the volatility associated with the patent protection of its key drug. At System.GURU.Markets, this metric is used in formulas for assessing the risks of companies with the same product.
Daily change in the price of a set of shares in a market segment - Neuro
Catalyst Pharmaceuticals, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to CPRX, which focuses on rare diseases, helps assess its risk compared to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Catalyst is a pharmaceutical company specializing in drugs for the treatment of rare neurological diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Catalyst's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Catalyst Pharmaceuticals
Catalyst is a biopharmaceutical company specializing in the treatment of rare diseases. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Neuro
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on treating rare neurological diseases. Its success depends on the commercialization of its key drug. The chart below shows how its niche strategy and portfolio expansion efforts are impacting its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Catalyst Pharmaceuticals is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. Its chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Catalyst Pharmaceuticals
The performance of Catalyst, a pharmaceutical company, depends on the success of its drugs. The monthly fluctuations on the chart reflect sales data for its flagship drug for a rare neuromuscular disease and news about efforts to expand its use, which is key to growth.
Monthly dynamics of market capitalization of the market segment - Neuro
Catalyst Pharmaceuticals is a commercial biopharmaceutical company specializing in drugs for the treatment of rare neuromuscular diseases. Unlike many biotech companies, it already has a product on the market. The dynamics of the pharmaceutical sector will provide a general backdrop against which to evaluate Catalyst's growth strategy through sales and drug portfolio expansion.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Catalyst Pharmaceuticals is a commercial pharmaceutical company focused on drugs for rare neuromuscular diseases. Its performance is less dependent on the economy. Given the market trends shown in the chart, Catalyst's performance is driven by sales growth of its key drug and success in expanding its use, rather than by general sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Catalyst Pharmaceuticals
Shares of Catalyst Pharmaceuticals, which specializes in rare neuromuscular diseases, are news-sensitive. Weekly performance depends on sales data for its key drug, the outcome of patent disputes, and regulatory decisions. The chart below shows how short-term events in a niche pharmaceutical company impact the company's valuation.
Weekly dynamics of market capitalization of the market segment - Neuro
How typical are Catalyst Pharmaceuticals' dynamics for the pharmaceutical sector? This chart compares the rare disease-focused company's weekly stock price movements to the industry average. This helps us understand whether its reaction to sales news and patent disputes is typical, or whether its niche specialization is creating a unique trajectory.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Catalyst Pharmaceuticals sells drugs for rare neuromuscular diseases. This chart compares its weekly performance to the market. It helps understand how its business, focused on a few approved products, provides stability compared to research-stage biotechs.
Market capitalization of the company, segment and market as a whole
CPRX - Market capitalization of the company Catalyst Pharmaceuticals
The Catalyst Pharmaceuticals valuation chart is an assessment of its business model, which is focused on treating rare neuromuscular diseases. The company's market capitalization is built on the success of its key drug, Firdapse. The dynamics clearly demonstrate how the market evaluates the commercial potential and life cycle of this orphan drug.
CPRX - Share of the company's market capitalization Catalyst Pharmaceuticals within the market segment - Neuro
Catalyst Pharmaceuticals specializes in drugs for rare neurological diseases. Its share of its sector market capitalization reflects the commercial success of its core product. The chart shows how investors assess its ability to defend its market niche and expand the use of its drugs, which directly impacts its industry weight.
Market capitalization of the market segment - Neuro
This chart shows the total value of pharmaceutical companies targeting rare neurological diseases. Catalyst Pharmaceuticals is a leader in its niche. The chart's dynamics reflect both the commercial success of its drug and the ongoing risks associated with patent protection.
Market capitalization of all companies included in a broad market index - GURU.Markets
The chart below shows the market value of helping patients with rare neurological diseases. Catalyst Pharmaceuticals' market value is a measure of its ability to discover and market drugs for very specific patient groups. The line demonstrates how its focus on neglected diseases creates its unique market share in global healthcare.
Book value capitalization of the company, segment and market as a whole
CPRX - Book value capitalization of the company Catalyst Pharmaceuticals
Catalyst Pharmaceuticals' book value represents its commercial and scientific capital. The chart below reflects the valuation of its rights to drugs for rare neuromuscular diseases and its commercial infrastructure. The dynamics demonstrate how the company is successfully monetizing its core asset and investing in portfolio expansion.
CPRX - Share of the company's book capitalization Catalyst Pharmaceuticals within the market segment - Neuro
Catalyst Pharmaceuticals's assets include R&D infrastructure and commercial capacity for advancing drugs for rare neuromuscular diseases. The chart shows the company's share of physical assets in its niche market, which, although small, is the foundation for serving patients with orphan diseases.
Market segment balance sheet capitalization - Neuro
Catalyst Pharmaceuticals is a commercial pharmaceutical company. Its business model is "light," focusing on drug development and commercialization while outsourcing manufacturing. The chart will show whether this structure is typical for the industry as a whole, or whether competitors prefer to own their own factories.
Book value of all companies included in the broad market index - GURU.Markets
Catalyst Pharmaceuticals' balance sheet is focused on commercializing drugs for rare neuromuscular diseases. The company's assets include infrastructure and rights to drugs that serve small but high-need patient populations, filling an important niche in the pharmaceutical industry.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Catalyst Pharmaceuticals
Catalyst Pharmaceuticals sells drugs for the treatment of rare neuromuscular diseases. Its market capitalization is based on monopoly rights to its key product. The chart shows how the market perceives the stability of this cash flow and the risks associated with potential competition or patent disputes.
Market to book capitalization ratio in a market segment - Neuro
Catalyst Pharmaceuticals is a commercial biopharmaceutical company focused on drugs for rare neuromuscular diseases. Its value is determined by the success of its lead drug. The chart shows how the market values its market share and potential for expanding its use.
Market to book capitalization ratio for the market as a whole
Catalyst Pharmaceuticals is a commercial biopharmaceutical company focused on treating rare neurological diseases. The chart shows how the market values a company that has successfully monetized its niche product. Its high market capitalization relative to its assets is based on the profitability of its single approved drug and its dominant market position.
Debts of the company, segment and market as a whole
CPRX - Company debts Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial biopharmaceutical company focused on treating rare neurological diseases. Its debt load may be related to its acquisition strategy for new drugs or to investments in expanding its commercial infrastructure for already approved products, as this chart illustrates.
Market segment debts - Neuro
Catalyst Pharmaceuticals is a commercial biopharmaceutical company specializing in the treatment of rare neurological diseases. Unlike many biotechs, Catalyst already has a revenue-generating product on the market. This chart shows the general norms for the pharmaceutical sector, allowing one to assess how the company reinvests profits into further research and business expansion.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial biopharmaceutical company focused on drugs for rare neurological diseases. Unlike many biotechs, Catalyst already has a profitable product. This chart demonstrates its strong financial position, allowing it to fund R&D and potential acquisitions internally.
Market segment debt to market segment book capitalization - Neuro
Catalyst Pharmaceuticals develops and commercializes drugs for the treatment of rare neurological diseases. This chart compares the company's debt to the total market capitalization of the entire neurological pharmaceutical sector. It helps evaluate how the company finances its niche products and ensures their availability to small patient groups.
Debt to book value of all companies in the market
Catalyst Pharmaceuticals operates in a niche market of rare neurological diseases. This chart compares its debt to the overall book value of the economy. It helps assess how the company finances its operations in the context of overall market conditions and how its financial model compares to pharmaceutical giants.
P/E of the company, segment and market as a whole
P/E - Catalyst Pharmaceuticals
This metric for Catalyst Pharmaceuticals, a company specializing in drugs for rare neuromuscular diseases, reflects the valuation of its niche business. It is sensitive to news about patent protection for its key product and potential competition. The chart shows how the market weighs its current monopoly position against future risks.
P/E of the market segment - Neuro
This chart shows the average valuation for the specialty pharmaceutical sector in which Catalyst Pharmaceuticals operates. This metric reflects how investors generally value companies operating in the rare disease niche. It helps us understand whether Catalyst's valuation reflects a premium for its leadership position.
P/E of the market as a whole
Catalyst Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare neurological diseases. The company focuses on niche markets with unmet medical needs. This risk appetite chart helps understand how investors value these niche companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Catalyst Pharmaceuticals
Catalyst Pharmaceuticals specializes in developing drugs to treat rare neuromuscular diseases. This chart reflects market expectations for sales of its lead drug and its success in expanding its use. It assesses the company's ability to dominate its narrow therapeutic niche.
%20P%2FE%20Catalyst%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Catalyst-Pharmaceuticals&v=1772513507922 "Chart of the company's future (projected) P/E Catalyst Pharmaceuticals")
Future (projected) P/E of the market segment - Neuro
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare neurological and neuromuscular diseases. Its lead product is designed to treat Lambert-Eaton syndrome. This chart shows overall market sentiment toward the biotech sector, helping to assess Catalyst's potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513507935 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Catalyst Pharmaceuticals is a commercial biopharmaceutical company specializing in drugs for the treatment of rare neurological diseases. Unlike companies in the development stage, Catalyst already has sales revenue. This makes it more stable, but growth still depends on the success of its drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513507944 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare neurological diseases. Its primary revenue is generated from sales of its single approved drug. This chart shows how the commercial success of a niche product and efforts to expand its use impact its financial performance.
Profit of companies in the market segment - Neuro
Catalyst Pharmaceuticals is a commercial biopharmaceutical company focused on developing and marketing drugs for rare neurological diseases. This chart shows the profitability of the neurology segment. With an approved drug on the market, the company generates revenue, which distinguishes it from many biotech companies. Its commercial success directly impacts its overall profitability.
Overall market profit
Catalyst Pharmaceuticals is a commercial biopharmaceutical company specializing in drugs for the treatment of rare neurological diseases. With an approved product on the market, its revenue depends on patient volume and access to treatment. This chart illustrates general economic cycles, while Catalyst's business is driven by specific healthcare needs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of rare neuromuscular diseases. The future profit projections shown in this chart depend on sales of its core commercial product and efforts to expand its use. It shows how analysts assess the company's potential in the niche pharmaceutical market.
%20profit%20of%20the%20company%20Catalyst%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Catalyst-Pharmaceuticals&v=1772513507971 "Graph of future (projected) profit of the company Catalyst Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Neuro
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare neurological and neuromuscular diseases. This chart shows revenue projections for the neurology segment. It reflects sales expectations for its key drug and the potential of new developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513507989 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Catalyst Pharmaceuticals develops drugs to treat rare neurological diseases. Demand for its products is driven by medical needs. However, the overall profit forecast reflected here impacts the investment climate in biotech and the solvency of the healthcare system. Stable economic growth provides funding for patient treatment.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513507998 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial biopharmaceutical company specializing in drugs for the treatment of rare neuromuscular diseases. Catalyst's P/S directly reflects the commercial success of its core product. The chart shows how investors view its sales performance and expansion strategy.
P/S market segment - Neuro
Catalyst Pharmaceuticals is a commercial biopharmaceutical company focused on treating rare neurological diseases. With an approved drug on the market, the company generates stable revenue. This chart shows how investors view the commercial success of their core product and their strategy for expanding their portfolio in the orphan disease niche.
P/S of the market as a whole
Catalyst Pharmaceuticals specializes in developing drugs for rare neurological diseases. The company's revenue is heavily dependent on the success of a single key drug. This chart illustrates the average revenue estimate, which helps understand how the market values the earnings of a pharmaceutical company with a concentrated product portfolio.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Catalyst Pharmaceuticals
Catalyst Pharmaceuticals specializes in developing drugs for rare neuromuscular diseases. Its success is built on a single key drug. This chart reflects investor expectations for this drug's future sales, given its dominant position in its niche and the company's efforts to expand its use.
%20P%2FS%20Catalyst%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Catalyst-Pharmaceuticals&v=1772513508077 "The graph of the company's future (projected) P/S Catalyst Pharmaceuticals")
Future (projected) P/S of the market segment - Neuro
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare neurological diseases. This chart shows how the market views the future sales of its approved drugs and development potential compared to other companies in the neuroscience sector, reflecting its focus on niche markets.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513508104 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Catalyst Pharmaceuticals develops drugs for the treatment of rare neurological diseases. The company has an approved drug, which is its primary source of revenue. This chart shows investors' overall revenue projections, and Catalyst exemplifies how successfully launching even one drug for an orphan disease can create a profitable business.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513508120 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare neurological diseases. This chart shows revenue from sales of its flagship product. Sales growth is driven by increasing the number of diagnosed patients and expanding access to treatment.
Sales of companies in the market segment - Neuro
Catalyst Pharmaceuticals is a company specializing in the treatment of rare neurological diseases. This chart shows the revenue from its flagship product, Firdapse. It allows investors to track sales trends and assess the company's success in commercializing its key drug for a niche market.
Overall market sales
Catalyst Pharmaceuticals is a commercial biopharmaceutical company specializing in the treatment of rare neurological diseases. With an approved drug on the market, its revenues are more stable than those of companies in development. This overall economic outlook has little impact on demand for its life-saving medications.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Catalyst Pharmaceuticals
Catalyst Pharmaceuticals specializes in drugs for rare neuromuscular diseases. Its revenue forecast is primarily driven by sales of its key product. This chart shows analysts' assessments of the stability of demand for this drug and the potential for expanding its use or introducing new products.
%20sales%20of%20the%20company%20Catalyst%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Catalyst-Pharmaceuticals&v=1772513508171 "Schedule of future (projected) sales of the company Catalyst Pharmaceuticals")
Future (projected) sales of companies in the market segment - Neuro
Catalyst Pharmaceuticals develops drugs to treat rare neurological diseases. This chart shows projected revenue for the entire neurological segment. It allows analysts to assess whether this market sees growth potential, which is crucial for the future commercial success of Catalyst's drugs and the expansion of their use.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513508178 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Catalyst Pharmaceuticals develops drugs to treat rare neuromuscular diseases. Demand for its products is not dependent on economic cycles, but is driven by patient needs. However, the overall economic situation, shown in the graph, influences healthcare pricing policies and insurers' decisions on reimbursement for expensive drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513508182 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Catalyst Pharmaceuticals
Catalyst Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of rare neurological diseases. This chart shows how the company monetizes its niche products. Its high profitability is driven by sales of its key drug, which faces limited market competition.
Market segment marginality - Neuro
Catalyst Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of rare neuromuscular diseases. This indicator reflects the commercial success of its core therapy. High profitability demonstrates a dominant position in its niche and a high demand for the proposed treatment.
Market marginality as a whole
Catalyst Pharmaceuticals is a commercial biopharmaceutical company focused on rare neurological diseases. With an approved drug, it generates revenue but continues research. This overall profitability chart reveals little about Catalyst's business, which depends on patent protection, regulatory approvals, and the needs of a small group of patients.
Employees in the company, segment and market as a whole
Number of employees in the company Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial biopharmaceutical company specializing in drugs for rare neuromuscular diseases. Following approval of its key product, the growth of its team reflects the creation and expansion of a sales force to promote it. This chart illustrates its commercial success.
Share of the company's employees Catalyst Pharmaceuticals within the market segment - Neuro
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare neurological and neuromuscular diseases. This chart highlights its narrow focus. It demonstrates the proportion of clinicians and researchers working to address the needs of patients with diseases like Lambert-Eaton syndrome that Catalyst shares.
Number of employees in the market segment - Neuro
Catalyst Pharmaceuticals is a biopharmaceutical company specializing in developing drugs for rare neurological diseases. This chart illustrates employment in neuroscience. The growing number of scientists in this field indicates a high demand for new treatments and a willingness to invest in developing drugs for patients with limited therapeutic options.
Number of employees in the market as a whole
Catalyst Pharmaceuticals is a commercial biopharmaceutical company focused on treating rare neurological diseases. The growth of its sales and marketing team is directly linked to the successful commercialization of its drugs. It is an example of how scientific research can be transformed into a business that creates jobs and benefits patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Catalyst Pharmaceuticals (CPRX)
Catalyst Pharmaceuticals is a commercial pharmaceutical company specializing in drugs for the treatment of rare neuromuscular diseases. Their high market value is supported by sales of a niche, patent-protected product. This chart shows that even with a sales team, intellectual property drives high per-employee costs in the pharmaceutical industry.
%20of%20the%20company%20Catalyst%20Pharmaceuticals%20(CPRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Catalyst-Pharmaceuticals-CPRX&v=1772513508403 "Chart of market capitalization per employee (in thousands of dollars) of the company Catalyst Pharmaceuticals (CPRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Catalyst Pharmaceuticals is a commercial pharmaceutical company focused on treating rare neurological diseases. Their success is built on the drug Firdapse. This chart shows the industry average. It helps estimate the market value generated by this niche, yet high-margin, commercial product per employee.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513508491 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Catalyst Pharmaceuticals is a commercial biopharmaceutical company specializing in drugs for the treatment of rare neurological diseases. Unlike research companies, Catalyst already has a product on the market. This chart reflects how the market perceives its commercial team's ability to successfully market and promote a highly targeted drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513508547 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Catalyst Pharmaceuticals (CPRX)
Catalyst Pharmaceuticals is a pharmaceutical company specializing in the treatment of rare neurological diseases. Its primary revenue comes from a drug for the treatment of Lambert-Eaton syndrome. This chart illustrates how profitable the orphan drug model can be: how a small team can generate significant profits selling a unique drug.
%20Chart%20Catalyst%20Pharmaceuticals%20(CPRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Catalyst-Pharmaceuticals-CPRX&v=1772513508650 "Company Profit Per Employee (in thousands of dollars) Chart Catalyst Pharmaceuticals (CPRX)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Catalyst Pharmaceuticals is a "specialty" pharma focused on treating "ultra-rare" neuromuscular diseases. This chart shows the benchmark for "specialty pharma." In this sector, the benchmark profit per employee is *astronomically* high. It's a "business monopoly," where a single patent on an "orphan drug" generates billions.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513508712 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Catalyst Pharmaceuticals specializes in treating rare neurological diseases. Their key drug, Firdapse, is used to treat LEMS. It's a niche pharmaceutical. This chart shows the market-average profit per employee. It helps understand how profitable the orphan neurology R&D sector, where Catalyst operates, is per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513508754 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Catalyst Pharmaceuticals (CPRX)
Catalyst Pharmaceuticals, a company specializing in rare neuromuscular diseases, demonstrates a successful commercial strategy in this chart. High revenue per employee is achieved through a focus on one key drug and effective outreach to a narrow circle of doctors and patients. This is an example of a successful niche business.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Catalyst-Pharmaceuticals-CPRX&v=1772513508782 "Sales chart per company employee Catalyst Pharmaceuticals (CPRX)")
Sales per employee in the market segment - Neuro
Catalyst Pharmaceuticals is a commercial pharmaceutical company specializing in the treatment of rare neuromuscular diseases. This chart shows the average revenue per employee in this segment. It helps assess how effectively Catalyst's small team monetizes its drugs in a narrow niche compared to other pharmaceutical companies.
Sales per employee for the market as a whole
Catalyst Pharmaceuticals (CPRX) is a pharmaceutical company focused on rare neurological diseases. The company has an approved drug, which is its primary source of revenue. This metric reflects how successfully Catalyst's small team is monetizing this drug. High values indicate the effectiveness of their commercial strategy.
Short shares by company, segment and market as a whole
Shares shorted by company Catalyst Pharmaceuticals (CPRX)
Catalyst Pharmaceuticals specializes in rare neurological diseases. Their primary revenue comes from a drug for the treatment of Lambert-Eaton syndrome. This chart shows the odds that their monopoly will end. Those who are bearish expect the emergence of generic competitors or court rulings that will strip the company of its exclusivity.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Catalyst-Pharmaceuticals-CPRX&v=1772513508849 "Short Shares Chart for the Company Catalyst Pharmaceuticals (CPRX)")
Shares shorted by market segment - Neuro
Catalyst Pharmaceuticals is a pharmaceutical company specializing in the treatment of rare neuromuscular diseases. Its success has long depended on a single drug. This chart highlights the pessimism in the pharmaceutical sector. The increase in short positions across the industry may reflect investor concerns about the patent protection of the company's key drug or the risks associated with bringing new products to market.
Shares shorted by the overall market
Catalyst Pharmaceuticals (CPRX) is a commercial-stage biopharmaceutical company specializing in drugs for rare neuromuscular diseases. The company is already generating revenue. This chart measures overall market pessimism. While demand for its drugs is stable, rising market fears could lead investors to fear competition or regulatory pressure, despite the defensive nature of the business.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Catalyst Pharmaceuticals (CPRX)
Catalyst Pharmaceuticals focuses on drugs for rare neurological diseases. Success depends on drug approvals and sales. A chart above 70 may reflect strong sales or positive news from the FDA. A level below 30 is often associated with trial failures or competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Catalyst-Pharmaceuticals-CPRX&v=1772513508960 "RSI 14 indicator chart for the company's stock Catalyst Pharmaceuticals (CPRX)")
RSI 14 Market Segment - Neuro
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the treatment of rare neurological and neuromuscular diseases, such as Lambert-Eaton myasthenic syndrome (LEMS). This chart shows the overall sentiment in the neuropharmaceutical sector. It helps assess how investors view this niche and how Catalyst stacks up against it.
RSI 14 for the overall market
Catalyst Pharmaceuticals (CPRX) is a pharmaceutical company focused on rare diseases. This schedule is less important to the company than regulatory decisions (e.g., the FDA). Demand for its life-saving drugs isn't affected by euphoria or panic. However, market panic could make it difficult to raise capital for R&D of new drugs.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CPRX (Catalyst Pharmaceuticals)
Catalyst Pharmaceuticals (CPRX) is a commercial-stage biopharmaceutical company specializing in the treatment of rare neuromuscular diseases. Its lead product is Firdapse. The chart shows the average target price. It reflects analysts' estimates of Firdapse's current sales and the company's potential for acquisitions to drive growth.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CPRX-Catalyst-Pharmaceuticals&v=1772513509097 "A chart showing analyst consensus forecasts for the expected stock price. CPRX (Catalyst Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price CPRX (Catalyst Pharmaceuticals)
Catalyst is a pharmaceutical company focused on treating rare neuromuscular diseases. Its primary revenue comes from Firdapse. This chart shows the gap between the market's current valuation of CPRX and analysts' perceptions of its value. This reflects their opinion of the drug's stability and new developments.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CPRX-Catalyst-Pharmaceuticals&v=1772513509140 "A chart showing the difference between the consensus forecast and the actual stock price. CPRX (Catalyst Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Neuro
Catalyst Pharma is a niche pharmaceutical company whose strategy is to acquire and commercialize drugs for rare neurological diseases. This chart shows analysts' overall expectations for the neuroscience sector, reflecting their belief in the success of this niche business model.
Analysts' consensus forecast for the overall market share price
Catalyst Pharmaceuticals (CPRX) is a biotech company with a single product (Firdapse) for the treatment of a rare neuromuscular disease. This chart, reflecting expert expectations, doesn't affect their demand (diseases are non-cyclical). However, it does impact the risk appetite of investors who fear competition for their single product.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Catalyst Pharmaceuticals
Catalyst is a pharmaceutical company focused on rare neurological diseases. Their main success is Firdapse, a drug for the treatment of Lambert-Eaton syndrome. This chart is an indicator of their niche monopoly. It likely reflects the sales growth of their flagship drug and their strategy to acquire other drugs for rare diseases.
AKIMA Market Segment Index - Neuro
Catalyst Pharma (CPRX) is a single-product biotech (for now); the company dominates the treatment of the ultra-rare autoimmune disease LEMS (the drug Firdapse). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this ultra-niche monopoly (LEMS) differentiate CPRX from the average pharma company?
The AKIM Index for the overall market
Catalyst is a pharmaceutical company focused on rare neurological diseases. Its success is built on a single key drug. It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative story stacks up against the backdrop of broader economic trends that influence risk appetite.
